Featured Image

Perspectives

We found in the tumors investigated no two identical tumors despite of the fact that most of them were clear cell renal cell carcinomas. At least it’s not such a surprise: what else can a tumor cell express than the genes which are already present. It seems to be, that tumor cells express several “tumor antigens” simultaneously, sometimes several in one cell, sometimes only s smaller number until it’s doesn’t inhibit the tumor cell proliferation. This was detectable by immunohistology, by FACS (not published but highly impressive in single tumor cell solutions in multiple staining methods), by FISH (not published: several subgroup could be identified: from none detectable aberration up to several aberrations). Therefore, we are expecting that a mono-target approach eliminates only the cell population expressing this target antigen. All other cells will survive and will be responsible for further tumors growth, for ongoing formation of metastasis. Tumors, at least RCC, consist of a mixture of several cell clones which need to get eradicated. Some will be cached by classical chemotherapy, other by single target immune-therapy … We need to find more multi-target approaches on one site and we have to find effective ways to stimulate the immune system to recognize the tumor as complete as possible. The autologous renal cell carcinoma vaccine used in already published studies (http://www.ncbi.nlm.nih.gov/pubmed/19876628) showed a 36 month prolonged overall survival.

Dr Stephan T. Kiessig
VCC Medical Deutschland GmbH

Read the Original

This page is a summary of: Tumor heterogeneity as a rationale for a multi-epitope approach in an autologous renal cell cancer tumor vaccine, OncoTargets and Therapy, January 2016, Dove Medical Press,
DOI: 10.2147/ott.s92182.
You can read the full text:

Read
Open access logo

Contributors

The following have contributed to this page